Cargando…

Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection

Streptococcus pneumoniae remains a leading cause of bacterial pneumonia despite the widespread use of vaccines. While vaccines are effective at reducing the incidence of most serotypes included in vaccines, a rise in infection due to nonvaccine serotypes and moderate efficacy against some vaccine se...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jiachen, Gingerich, Aaron D., Royer, Fredejah, Paschall, Amy V., Pena-Briseno, Alma, Avci, Fikri Y., Mousa, Jarrod J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091081/
https://www.ncbi.nlm.nih.gov/pubmed/33649050
http://dx.doi.org/10.1128/IAI.00747-20
_version_ 1783687412240613376
author Huang, Jiachen
Gingerich, Aaron D.
Royer, Fredejah
Paschall, Amy V.
Pena-Briseno, Alma
Avci, Fikri Y.
Mousa, Jarrod J.
author_facet Huang, Jiachen
Gingerich, Aaron D.
Royer, Fredejah
Paschall, Amy V.
Pena-Briseno, Alma
Avci, Fikri Y.
Mousa, Jarrod J.
author_sort Huang, Jiachen
collection PubMed
description Streptococcus pneumoniae remains a leading cause of bacterial pneumonia despite the widespread use of vaccines. While vaccines are effective at reducing the incidence of most serotypes included in vaccines, a rise in infection due to nonvaccine serotypes and moderate efficacy against some vaccine serotypes have contributed to high disease incidence. Additionally, numerous isolates of S. pneumoniae are antibiotic or multidrug resistant. Several conserved pneumococcal proteins prevalent in the majority of serotypes have been examined for their potential as vaccines in preclinical and clinical trials. An additional, yet-unexplored tool for disease prevention and treatment is the use of human monoclonal antibodies (MAbs) targeting conserved pneumococcal proteins. Here, we isolated the first human MAbs (PhtD3, PhtD6, PhtD7, PhtD8, and PspA16) against the pneumococcal histidine triad protein (PhtD) and the pneumococcal surface protein A (PspA), two conserved and protective antigens. MAbs to PhtD target diverse epitopes on PhtD, and MAb PspA16 targets the N-terminal segment of PspA. The PhtD-specific MAbs bind to multiple serotypes, while MAb PspA16 serotype breadth is limited. MAbs PhtD3 and PhtD8 prolong the survival of mice infected with pneumococcal serotype 3. Furthermore, MAb PhtD3 prolongs the survival of mice in intranasal and intravenous infection models with pneumococcal serotype 4 and in mice infected with pneumococcal serotype 3 when administered 24 h after pneumococcal infection. All PhtD and PspA MAbs demonstrate opsonophagocytic activity, suggesting a potential mechanism of protection. Our results identify new human MAbs for pneumococcal disease prevention and treatment and identify epitopes on PhtD and PspA recognized by human B cells.
format Online
Article
Text
id pubmed-8091081
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-80910812021-05-18 Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection Huang, Jiachen Gingerich, Aaron D. Royer, Fredejah Paschall, Amy V. Pena-Briseno, Alma Avci, Fikri Y. Mousa, Jarrod J. Infect Immun Microbial Immunity and Vaccines Streptococcus pneumoniae remains a leading cause of bacterial pneumonia despite the widespread use of vaccines. While vaccines are effective at reducing the incidence of most serotypes included in vaccines, a rise in infection due to nonvaccine serotypes and moderate efficacy against some vaccine serotypes have contributed to high disease incidence. Additionally, numerous isolates of S. pneumoniae are antibiotic or multidrug resistant. Several conserved pneumococcal proteins prevalent in the majority of serotypes have been examined for their potential as vaccines in preclinical and clinical trials. An additional, yet-unexplored tool for disease prevention and treatment is the use of human monoclonal antibodies (MAbs) targeting conserved pneumococcal proteins. Here, we isolated the first human MAbs (PhtD3, PhtD6, PhtD7, PhtD8, and PspA16) against the pneumococcal histidine triad protein (PhtD) and the pneumococcal surface protein A (PspA), two conserved and protective antigens. MAbs to PhtD target diverse epitopes on PhtD, and MAb PspA16 targets the N-terminal segment of PspA. The PhtD-specific MAbs bind to multiple serotypes, while MAb PspA16 serotype breadth is limited. MAbs PhtD3 and PhtD8 prolong the survival of mice infected with pneumococcal serotype 3. Furthermore, MAb PhtD3 prolongs the survival of mice in intranasal and intravenous infection models with pneumococcal serotype 4 and in mice infected with pneumococcal serotype 3 when administered 24 h after pneumococcal infection. All PhtD and PspA MAbs demonstrate opsonophagocytic activity, suggesting a potential mechanism of protection. Our results identify new human MAbs for pneumococcal disease prevention and treatment and identify epitopes on PhtD and PspA recognized by human B cells. American Society for Microbiology 2021-04-16 /pmc/articles/PMC8091081/ /pubmed/33649050 http://dx.doi.org/10.1128/IAI.00747-20 Text en Copyright © 2021 American Society for Microbiology. https://doi.org/10.1128/ASMCopyrightv2All Rights Reserved (https://doi.org/10.1128/ASMCopyrightv2) .
spellingShingle Microbial Immunity and Vaccines
Huang, Jiachen
Gingerich, Aaron D.
Royer, Fredejah
Paschall, Amy V.
Pena-Briseno, Alma
Avci, Fikri Y.
Mousa, Jarrod J.
Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection
title Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection
title_full Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection
title_fullStr Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection
title_full_unstemmed Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection
title_short Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection
title_sort broadly reactive human monoclonal antibodies targeting the pneumococcal histidine triad protein protect against fatal pneumococcal infection
topic Microbial Immunity and Vaccines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091081/
https://www.ncbi.nlm.nih.gov/pubmed/33649050
http://dx.doi.org/10.1128/IAI.00747-20
work_keys_str_mv AT huangjiachen broadlyreactivehumanmonoclonalantibodiestargetingthepneumococcalhistidinetriadproteinprotectagainstfatalpneumococcalinfection
AT gingerichaarond broadlyreactivehumanmonoclonalantibodiestargetingthepneumococcalhistidinetriadproteinprotectagainstfatalpneumococcalinfection
AT royerfredejah broadlyreactivehumanmonoclonalantibodiestargetingthepneumococcalhistidinetriadproteinprotectagainstfatalpneumococcalinfection
AT paschallamyv broadlyreactivehumanmonoclonalantibodiestargetingthepneumococcalhistidinetriadproteinprotectagainstfatalpneumococcalinfection
AT penabrisenoalma broadlyreactivehumanmonoclonalantibodiestargetingthepneumococcalhistidinetriadproteinprotectagainstfatalpneumococcalinfection
AT avcifikriy broadlyreactivehumanmonoclonalantibodiestargetingthepneumococcalhistidinetriadproteinprotectagainstfatalpneumococcalinfection
AT mousajarrodj broadlyreactivehumanmonoclonalantibodiestargetingthepneumococcalhistidinetriadproteinprotectagainstfatalpneumococcalinfection